Your session is about to expire
← Back to Search
Carvedilol for Preventing Heart Problems in HER2 Positive Breast Cancer
Study Summary
This trial studies the effects of carvedilol on preventing heart problems in patients with HER2-positive breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your heart's pumping ability must be at least 50% as measured by a special heart ultrasound within 28 days before joining the study.Your liver enzyme levels are within five times the normal range.I can swallow pills.I have no cancer history except for certain treated cancers or those I've been free from for 5 years.You need to have had an electrocardiogram within the last 28 days to check your heart's electrical activity.I have metastatic breast cancer and am on or starting a trastuzumab-based treatment without anthracyclines.I am not taking and do not plan to take certain medications during the study.I can take care of myself and am up and about more than 50% of my waking hours.Your bilirubin level in the blood is not more than three times the normal limit.I do not require dialysis.My asthma is under control.I haven't used beta blockers, ARBs, or ACE inhibitors in the last 21 days.I am at high risk for heart issues due to previous treatments or health conditions.I had a full physical exam and medical history review within the last 28 days.My heart's pumping ability is confirmed to be good by a special heart test.Your blood pressure must be at least 80 mm Hg before joining the study.
- Group 1: Arm I (carvedilol)
- Group 2: Arm II (no intervention)
- Group 3: Arm III (observation)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Laboratory Biomarker Analysis carry any risks for patients?
"There is some evidence of efficacy and multiple rounds of data supporting safety, meaning that Laboratory Biomarker Analysis scores a 3 on our team's 1-3 scale."
Are there any patients who have yet to enroll in this clinical trial?
"That is accurate. According to the information available on clinicaltrials.gov, this study was first advertised on September 15th, 2017 and is still recruiting patients. They are looking for 817 individuals total, across 100 different centres."
What can researchers learn from Laboratory Biomarker Analysis studies?
"Currently, there are 29 different ongoing trials that involve laboratory biomarker analysis. Out of these, 7 are in phase 3. Most of the clinical trials related to this topic are based in Orlando, Florida; however, there are 978 locations around the world conducting similar research."
What does Laboratory Biomarker Analysis test for?
"Biomarker analysis can be used in laboratory settings to treat hypertensive disease, heart failure, and hypesthesia."
In how many different places is this trial taking place?
"There are over 100 hospitals and medical centres around the country participating in this clinical trial, such as University of Kansas Cancer Center-Overland Park, University of Kansas Cancer Center at North Kansas City Hospital, Woman's Hospital, and many others."
How many people are taking part in this experiment at most?
"Yes, as indicated on clinicaltrials.gov, this trial is open for recruitment. This particular study was posted on September 15th, 2017 and updated November 9th of this year. They are looking to enroll 817 patients from 100 different sites."
Share this study with friends
Copy Link
Messenger